Clppr
Patent retention comings and goings can influence patient revenue calculations considerably.Using the 862 patients in therapy as an average for your Q1 2024 revenue per patient looks a bit optimistic to me in view of the info below:
*Approximately 25% of the 5,000[1250] diagnosed Rett syndrome patients in the United States[Q1 2024] have initiatedtherapy.[Refer Neuren].
*1250 patients were mentioned in Acadia’s last earnings call and post-call fireside chats. 1300+ patients was reached at the end of Q1 according to this letter from Acadia to the Retts community in early June (taken from the dedicated Daybue website).Refer Kryptonite]
Patients mentioned above were all paying customers.
Kens
Acadia, page-707
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.30 |
Change
0.760(4.59%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.35 | $17.94 | $17.25 | $17.64M | 1.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2533 | $17.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.45 | 1254 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |